Business Context and Reporting Period
This Form 8-K was filed by Ekso Bionics Holdings, Inc. on January 8, 2019. The filing serves to announce preliminary financial results for the quarter and full year ended December 31, 2018. The registrant is incorporated in Nevada and identifies as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that the preliminary results are detailed in a press release attached as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
No material changes or comparative financial data are disclosed within the body of this Form 8-K. The filing acts solely as a notification that results for the period ended December 31, 2018, have been reported.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors. It includes a standard disclaimer stating that the information furnished in this report and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 8, 2019) for the actual preliminary financial figures for Q4 and FY 2018.
- Verify the company's status as an emerging growth company and any associated accounting transition elections.
- Confirm the identity of the signatory, John Glenn, as the Chief Financial Officer.
- Note that the filing date (Jan 8, 2019) differs from the press release date listed in the exhibit description (Jan 8, 2018), which may indicate a typographical error in the exhibit description requiring verification.